Abbott Laboratories Announces Second-Quarter 2025 Results and Guidance

Details

GAAP diluted EPS was $1.01, while adjusted diluted EPS was $1.26, reflecting double-digit growth compared to the prior year. Abbott also provided guidance for the full year 2025, projecting organic sales growth of 7.5% to 8.0% excluding COVID-19 testing-related sales and adjusted diluted EPS of $5.10 to $5.20. Abbott's management uses non-GAAP financial measures to provide greater visibility on the results of operations excluding certain costs, such as intangible amortization expense, to better evaluate ongoing business performance.

Items reported

Exhibits (1)

About Abbott Laboratories

Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.